

Initiating NERLYNX therapy: Timing matters

Breast cancer patients with HER2+/HR- tumours can still benefit from neratinib therapy, provided treatment is initiated within 6 months of trastuzumab therapy. We spoke with Dr Bent Ejlertsen from the Rigshospitalet, Copenhagen at ASCO 2018.

Watch the interview by clicking the link below.

